14 min listen
Very long-term follow-up of FCR therapy for CLL, risk assessment of KMT2A-rearranged B-cell precursor ALL in adults; anti-myeloma therapy using antibo…
FromBlood Podcast
Very long-term follow-up of FCR therapy for CLL, risk assessment of KMT2A-rearranged B-cell precursor ALL in adults; anti-myeloma therapy using antibo…
FromBlood Podcast
ratings:
Length:
25 minutes
Released:
Nov 23, 2023
Format:
Podcast episode
Description
On this week's episode we’ll discuss the findings from a long-term follow up study of fludarabine, cyclophosphamide, and rituximab in IGHV-mutated CLL, learn more about the impact of genetic alterations and minimal residual disease in adults with KMT2A-rearranged B-cell precursor ALL, and discuss a pre-clinical study of reinforced immunotherapy for myeloma using a new bispecific antibody-based approach.
Released:
Nov 23, 2023
Format:
Podcast episode
Titles in the series (100)
Season 1, Episode 1: This episode will highlight a unique treatment for refractory hematologic malignancies, therapy-induced mutations impacting the genomic landscape of relapsed acute lymphoblastic leukemia, and a unique approach to avoiding chronic graft-versus-host disease by Blood Podcast